Watchlist · 65/100Aug 11, 12:50 PM EDT
Autolus Guides 2026 AUCATZYL Sales to $140M-$150M, Sees 65%-70% Gross Margin
AUTL
Autolus Therapeutics reported Q2 2026 AUCATZYL revenue of $45.7 million, up from $26 million in the prior year, and guided full-year 2026 sales to $140-$150 million. Management also targets a 65%-70% gross margin within 12-18 months, signaling strong commercia…
- ▹AUCATZYL commercial launch showing strong growth with 2026 guidance of $140-150M, indicating real demand and reimbursement traction.
- ▹Single-asset company with no recent regulatory negatives, but lacks platform diversification and faces manufacturing scale-up risks.
Neutral · 64/100Aug 10, 8:59 PM EDT
BridgeBio Sets Sights on Triple Launch, Key Data Readout by 2028
BBIO
BridgeBio Pharma (BBIO) outlined plans for three product launches, with the first PDUFA date set for November 27, 2026, and expects the RECLAIM-HP trial readout within 18 months. CEO Neil Kumar highlighted the company's transition to a new growth phase, emphas…
- ▹Multiple pipeline catalysts including PDUFA date and phase 3 readout, but single-asset focus and long timeline cap upside.
- ▹Commercialized product (Attruby) provides some revenue, but limited differentiation and no major platform advantage.
Neutral · 57/100Aug 12, 1:19 AM EDT
Mineralys Therapeutics Prepares for Lorundrostat Launch, Cash Runway Extends to 2028
MLYS
Mineralys Therapeutics (MLYS) is prioritizing commercial launch readiness for lorundrostat ahead of its December 22, 2026 PDUFA date, while also exploring partnering opportunities and advancing clinical development. The company's cash runway extends into 2028,…
- ▹PDUFA date set with cash runway into 2028, but single-asset company with no FDA approval yet.
- ▹Commercial launch readiness and partnering opportunities are positive, but no differentiated platform or manufacturing edge.
Neutral · 57/100Aug 11, 12:49 PM EDT
Silence Therapeutics' Divesiran Shows Best-in-Class Potential; Morgan Stanley Reaffirms Overweight
SLNPTGX
Morgan Stanley reiterated its Overweight rating on Silence Therapeutics (SLN) following Phase 2 data for divesiran in polycythemia vera, which analysts believe could be best-in-class. The firm raised its price target, signaling confidence in the drug's efficac…
- ▹Phase 2 data suggests best-in-class potential, but still early-stage and single-asset focus.
- ▹Morgan Stanley maintains Overweight, but no regulatory or commercial milestones yet.
Neutral · 55/100Aug 11, 11:58 AM EDT
Bicara Sets Mid-2027 Interim Readout, Kicks Off FORTIFI-FLEX, and Appoints New C-Suite
BCAX
Bicara Therapeutics (BCAX) provided an update on its pivotal Phase III FORTIFI-HN01 study, with an interim analysis expected by mid-2027, and initiated the FORTIFI-FLEX trial. The company also announced new CEO and CFO appointments, signaling a strategic shift…
- ▹Phase III pivotal study ongoing with interim analysis planned, but no regulatory clarity yet.
- ▹Single-asset company with new management, limited diversification.
Neutral · 50/100Aug 12, 1:37 AM EDT
Silence Therapeutics Raises $175M in Upsized ADS Offering
SLN
Silence Therapeutics (SLN) priced an upsized public offering of 12.96 million ADSs at $13.50 each, raising approximately $175 million in gross proceeds. The underwriters have a 30-day option to buy an additional 1.94 million ADSs. This capital raise provides f…
- ▹Capital raise provides runway but dilutes existing shareholders.
- ▹Single-asset platform with no recent regulatory or commercial catalysts.
Neutral · 50/100Aug 11, 9:38 PM EDT
Taysha Sets REVEAL Interim Readout and FDA Dialogue for H1 2027, PPQ Targeted for Q4 2026
TSHA
Taysha Gene Therapies (TSHA) completed dosing in its pivotal REVEAL and ASPIRE trials during Q2 2026, with a 6-month interim analysis and FDA feedback expected in H1 2027. The company targets process performance qualification (PPQ) completion in Q4 2026, a key…
- ▹Pivotal trial completion and FDA feedback expected in H1 2027, but no accelerated path or surrogate endpoint mentioned.
- ▹Single-asset gene therapy company with limited platform diversification and no recent BD/M&A.
Neutral · 50/100Aug 11, 7:48 PM EDT
Absci Projects ABS-201 Interim Data by Late 2026, Extends Cash Runway to 2028
ABSI
Absci (ABSI) announced that interim proof-of-concept data for its lead candidate ABS-201 is expected in the second half of 2026, with cash runway extended into the second half of 2028. The company also reported positive interim Phase I data from the HEADLINE t…
- ▹Phase I data positive but early; regulatory path not accelerated.
- ▹Platform company with differentiated tech, but single-asset focus and long timeline to data.
Neutral · 50/100Aug 11, 1:39 AM EDT
IMDX Projects ~$8M Quarterly Cash Burn in H2 2026, Eyes FDA Nod for GraftAssureDx
IMDX
Insight Molecular Diagnostics (IMDX) expects a cash burn of approximately $8 million per quarter in the second half of 2026, while reiterating its target for FDA marketing authorization of its GraftAssureDx product later this year. The company's CEO expressed…
- ▹FDA authorization targeted for GraftAssureDx, but no accelerated path or surrogate endpoint mentioned.
- ▹Single-asset micro-cap with high cash burn and dilution risk, offset by clear regulatory catalyst.
Neutral · 50/100Aug 10, 4:14 PM EDT
Silence Therapeutics Announces $150M ADS Offering to Fund Pipeline
SLN
Silence Therapeutics (SLN) has initiated an underwritten public offering of approximately $150 million in American Depositary Shares (ADSs), with each ADS representing three ordinary shares. The company also plans to grant underwriters an option to purchase ad…
- ▹Dilutive offering raises capital but signals potential cash runway concerns.
- ▹Platform technology with multiple assets, but no recent clinical or regulatory catalysts.
High Risk · 49/100Aug 10, 12:59 PM EDT
Tonix Advances TNX-4800 into Large Phase II Trial, Expands TONMYA Sales Force to 150 by September
TNXP
Tonix Pharmaceuticals (TNXP) announced plans for a Phase II trial of TNX-4800 involving approximately 3,300 participants, while scaling its TONMYA sales force to about 150 representatives by September. Management highlighted TONMYA's strong launch progress, in…
- ▹TONMYA is a commercialized product for fibromyalgia, but TNX-4800 is a single-asset Phase II with a large trial and no clear regulatory advantages.
- ▹Scaling sales force to 150 reps suggests commercial investment, but financial runway and dilution risks remain high for a micro-cap.
High Risk · 49/100Aug 10, 12:09 PM EDT
Heron Therapeutics Projects $24.3M Cash Post-Debt Payment, Details 2027 Covenants
HRTX
Heron Therapeutics (HRTX) reported Q2 2026 net revenue of $37.7 million, below internal expectations, with CINVANTI sales up sequentially and ZYNRELEF growing. The company outlined debt covenants through 2027 and expects pro forma cash of $24.3 million after a…
- ▹Revenue miss and weak guidance highlight commercial challenges; cash runway concerns with only $24.3M pro forma cash.
- ▹No major regulatory or technology catalysts; single-asset focus and dilution risk weigh on narrative.
High Risk · 45/100Aug 11, 5:08 PM EDT
Imunon Provides OVATION 3 Enrollment Update and Sets Early 2027 for OVATION 2 Data Release
IMNN
Imunon (IMNN) reported that its OVATION 3 trial is enrolling at a rate of 0.5 patients per site per month, while planning to present OVATION 2 data in early 2027. The updates highlight progress for its lead asset IMNN-001 and TheraPlas platform, which are key…
- ▹Single-asset micro-cap with early-stage pipeline, limited regulatory clarity.
- ▹Slow enrollment and distant data readouts cap near-term upside.
High Risk · 45/100Aug 11, 1:48 PM EDT
Intensity Therapeutics Sets 2027 Target for INVINCIBLE-4 Enrollment, Seeks $30M to Complete Phase 3 Trial
INTS
Intensity Therapeutics (INTS) aims to complete enrollment in its INVINCIBLE-4 study by the end of 2027, while seeking $30 million in funding to finish the INVINCIBLE-3 trial. The company provided updates on its clinical programs and business development during…
- ▹Single-asset clinical-stage company with no approved products, relying on external funding.
- ▹Long timeline to enrollment completion (2027) and need for $30M financing indicate high dilution risk.
High Risk · 45/100Aug 11, 11:48 AM EDT
DiaMedica's ReMEDy2 Trial Enrollment Hits 85% of Target, Interim Analysis Expected by Early 2027
DMAC
DiaMedica Therapeutics (DMAC) announced that enrollment in its ReMEDy2 trial for DM199 in acute ischemic stroke has surpassed 85% of the 200-patient trigger, with an interim analysis anticipated in Q1 2027. This milestone brings the company closer to a potenti…
- ▹Single-asset clinical-stage biotech with no FDA regulatory milestones near-term; interim analysis not until Q1 2027.
- ▹Enrollment progress is positive but lacks commercial validation and manufacturing scale; high dilution risk.
High Risk · 37/100Aug 12, 2:24 AM EDT
Silexion Therapeutics Announces $2.5M Public Offering Pricing
SLXN
Silexion Therapeutics (SLXN) has priced a public offering of approximately 3.85 million ordinary shares (or equivalents) and Series E warrants at a combined price of $0.65 per share, raising about $2.5 million. The offering provides capital for the company's o…
- ▹Priced a $2.5M public offering, indicating significant dilution risk and potential cash runway concerns.
- ▹Single-asset micro-cap with no clear regulatory or commercial catalysts; high risk profile.
High Risk · 37/100Aug 11, 4:41 PM EDT
Apollomics Secures $10M in Private Placement with CEO Note Conversion
APLM
Apollomics (APLM) has entered into agreements for a private placement expected to raise approximately $10 million, consisting of $8 million in cash from the sale of 533,334 Class A shares at $15 each, and the conversion of a $2 million convertible note held by…
- ▹Small $10M raise signals cash runway concerns and dilution risk.
- ▹Single-asset micro-cap with no recent regulatory or commercial catalysts.
High Risk · 37/100Aug 11, 2:13 PM EDT
Intel and Gilead Get Analyst Nods: AI Funding and HIV Strength Drive Upgrades
AMDINTC
Intel received a bullish upgrade from analyst Bill Maurer, who highlights the company's massive equity raise to support its AI initiatives. Meanwhile, ALLKA Research upgraded Gilead Sciences to Buy after strong Q2 results, with the HIV franchise and newer prod…
- ▹News is analyst upgrades/downgrades, not company-specific catalysts; limited regulatory or technology details.
- ▹Intel's equity raise for AI is a positive narrative but carries dilution risk; Gilead's upgrade is commercial but not detailed.
High Risk · 32/100Aug 11, 12:13 PM EDT
Short Squeeze Watch: Top Heavily Shorted Stocks to Monitor
WOLFPRPLJBLUPLUG
The article highlights the most heavily shorted stocks, including Wolfspeed (WOLF), Purple Innovation (PRPL), JetBlue (JBLU), and Plug Power (PLUG). Investors are weighing whether these companies face fundamental troubles or are candidates for short squeezes,…
- ▹No specific regulatory catalysts; generic short interest heatmap with no FDA news.
- ▹Multiple single-asset or troubled companies with high short interest, indicating negative sentiment and potential dilution risks.
High Risk · 30/100Aug 10, 2:59 PM EDT
Trump signs executive order overhauling pediatric vaccine schedule, splitting MMR
MRKGSK
President Trump signed an executive order that restructures the childhood vaccine schedule, notably separating the combined MMR vaccine into individual doses. This policy shift could affect vaccine manufacturers like Merck (MRK) and GlaxoSmithKline (GSK), pote…
- ▹Executive order disrupts vaccine schedule, creating regulatory uncertainty for MRK and GSK.
- ▹Potential negative impact on demand for combination vaccines, but established products and manufacturing remain.